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ABSTRACT
Background Fragile X syndrome (FXS) is a well-
known X-linked disorder clinically characterized by 
intellectual disability and autistic features. However, 
diagnosed Japanese FXS cases have been fewer than 
expected, and clinical features of Japanese FXS patients 
remain unknown.
Methods We evaluated the clinical features of 
Japanese FXS patients using the results of a question-
naire-based survey.
Results We presented the characteristics of seven 
patients aged 6 to 20 years. Long face and large ears 
were observed in five of seven patients. Macrocephaly 
was observed in four of five patients. The meaningful 
word was first seen at a certain time point between 18 
and 72 months (median = 60 months). Developmental 
quotient or intellectual quotient ranged between 20 and 
48 (median = 29). Behavioral disorders were seen in 
all patients (autistic spectrum disorder in six patients, 
hyperactivity in five patients). Five patients were diag-
nosed by polymerase chain reaction analysis, and two 
patients were diagnosed by the cytogenetic study. All 
physicians ordered FXS genetic testing for suspicious 
cases because of clinical manifestations.
Conclusion In the present study, a long face, large 
ears, macrocephaly, autistic spectrum disorder, and 
hyperactivity were observed in almost cases, and these 
characteristics might be common features in Japanese 
FXS patients. Our finding indicated the importance 
of clinical manifestations to diagnosis FXS. However, 
the sample size of the present study is small, and these 
features are also seen to patients with other disorders. 
We consider that genetic testing for FXS should be per-
formed on a wider range of intellectually disabled cases.
Key words CGG repeat expansion; FMR1 gene; frag-
ile X syndrome; genetic testing; intellectual disability
Fragile X syndrome (FXS) (OMIM #300624) is a well-
known X-linked disorder clinically characterized by in-
tellectual disability and autistic features. In Japan, FXS 
(no. 206) and the related disorders (FXTAS and FXPOI) 
(no. 205) was authorized as designated intractable 
diseases in July 2015, and the genetic testing was ac-
cepted as national health insurance in April 2016. Well-
known physical phenotypes of FXS are the long face, 
macrocephaly, mandibular prognathism, and large ears.1 
However, these physical features are manifested mostly 
in boys and tend to become more marked with age.1 
Additionally, these features may not be clinically notice-
able in every patient. The FXS phenotype is caused 
by inactivation of the FMR1 gene, which consists, in 
an expansion above 200 CGG at the 5’ untranslated 
region (5′ UTR) repeat and subsequent methylation of 
the CGG triplets and CpG island in the promotor region 
of the gene.1 Because disease-specific clinical features 
are unknown, genetic testing to detect more than 200 
CGG repeat expansion (full mutation) of FMR1 gene is 
necessary for the diagnosis of FXS, except for the rare 
patients with the intragenic pathogenic variant in FMR1 
gene.2, 3
Prevalence of the FMR1 full mutation in male is 
1 in 7,143 and in female is 1 in 11,111. Prevalence of 
FXS is varied by ethnicity.4 In Asian countries, the 
prevalence of FXS patients is thought to be smaller than 
that of Western countries.5, 6 The prevalence of Japanese 
FXS patients in males is estimated to be approximately 
1 in 10,000, and this predicted prevalence of FXS in 
Japan is lower than Caucasian populations.4 In Japan, 
several reports have been published about Japanese 
FXS patients.7–9 However, the detailed clinical features 
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of Japanese FXS patients are unknown. This is the first 
case series of the phenotypes in Japanese FXS cases.
SUBJECTS AND METHODS
To elucidate the clinical characteristics of Japanese 
FXS patients, we analyzed the results of a nationwide 
questionnaire-based survey in Japan. The first set of 
questionnaires, which focused on the experience of 
patients with FXS, was sent to Japanese specialists for 
pediatrics and pediatric neurology. The second set of 
questionnaires, which focused on the clinical informa-
tion of patients with FXS, was sent to their attending 
physicians. The clinical data collected from the second-
ary questionnaire included developmental, behavioral, 
and physical assessment (Patient 3, 4, 5, 6 and 7 in 
Table 1). The clinical information of Family A (Patients 
1 and 2 in Table 1) was not collected from nationwide 
questionnaire survey, and we collected the clinical in-
formation from the attending physician using the same 
questionnaire.
Macrocephaly was defined as a head circumfer-
ence of more than 2 standard deviations based on 
age and gender, or subjective findings by the attend-
ing physician. PCR-based genetic testing of FMR1 
gene was performed as previously described at a 
Tottori University (Patient 1, 2 and 3).7 PCR-based 
genetic testing of Patient 4 and 5 was performed using 
FragilEaseTM PCR assay at a registered clinical labora-
tory. Cytogenetic study was performed at registered 
clinical laboratory (Patient 6 and 7). All surveys and 
experiments performed in this study were approved by 
the Ethical Committee of Tottori University (approval 
number G81, G170, and G171).
RESULTS
Table 1 shows a clinical summary of the patients in our 
series. The seven patients from five families were male, 
participated from 2011 to 2016. The age at the time of 
examination ranged from 6 to 20 years old. The follow-
ing facial features were observed in almost all patients: 
macrocephaly (four patients), long face (five patients), 
large ears (five patients), and mandibular prognathism 
(four patients). The head circumstance was accessed by 
the scale of Japanese standard head circumstances, and 
macrocephaly was observed in Patient 6. Additionally, 
subjective findings of macrocephaly were observed in 
Patient 1, 2 and 7. Epilepsy was observed in Patient 7. 
Walking was first seen at a certain time point between 
Table 1. Clinical features of Japanese patients with fragile X syndrome
Family A B C D E
Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age 9 y 8 y 8 y 20 y 20 y 6 y 9 y
Age at assessment 9 y 0 m 5 y 11 m 7 y 1 m 20 y 20 y 5 y 0 m 6 y 8 m
Sex Male Male Male Male Male Male Male
Macrocephaly + + − Unknown Unknown + +
Facial features Prominent 
forehead, 




















Epilepsy − − − − − − +
Meaningful words 1 y 6 m 4 y 6 y 6 y 6 y 3 y -














DQ/IQ DQ 43 DQ 20 IQ 48 IQ 20 IQ 29 DQ 37 DQ 17






None None Hypospadias None




DQ was assessed by the Kyoto Scale of Psychological Development 2001. IQ was assessed by Tanaka–Binet Intelligence Test. ASD, 
autistic spectrum disorder; DQ, developmental quotient; IQ, intellectual quotient; m, month(s); y, year(s).
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12 and 18 months (median = 18 months). The meaning-
ful word was first observed at a certain time point be-
tween 18 and 72 months (median = 60 months). Patient 
7 did not utter any meaningful word at the age of 18. 
Developmental quotient (DQ) and intellectual quotient 
(IQ) were assessed by the Kyoto Scale of Psychological 
Development 2001 and Tanaka–Binet Intelligence Test, 
respectively. IQ/DQ ranged between 20 and 48 (median 
= 29). Behavioral disorders were seen in all seven 
patients (hyperactivity in five patients, autistic spectrum 
disorder in six patients, harm to others in one patient, 
euphoria in one patient). Five patients were diagnosed 
by polymerase chain reaction analysis, and two patients 
were diagnosed by the cytogenetic study. The reason 
why each physician ordered the testing was as follows. 
In five families, three families (Family C, D and E) have 
patients with facial features and abnormal behavior, 
one family (Family A) has patients with facial features, 
abnormal behavior and family history (Patient 1 and 2), 
and one family (Family B) has a patient with abnormal 
behavior and family history (an uncle has an intellectual 
disability).
DISCUSSION
We show a comparison between clinical features of 
present FXS case series and description in recent review 
collected from 15 articles,10 showing the prevalence 
according to phenotypes, facial features, behavioral 
features, intellectual disability, and epilepsy (Table 
2). In FXS patients, facial phenotypes are seen more 
commonly in adult patients.1 However, these features 
were manifested in all four pediatric patients (Patients 
1, 2, 6, and 7 in Table 1). The evident variability of clini-
cal features due to ethnicity differences is unknown. 
Charalsawadi et al.6 described the elongated face of 
FXS patients in Korea and Thailand was less significant 
than that of the American population. Conversely, large 
ears were more significant in FXS patients in Korea 
and Thailand. Both the elongated face and large ears 
were equally seen in our patients. However, in the 
present study, most attending physicians suspected 
FXS based on the patient’s facial features, and this 
high frequency of facial features in the present series 
might not reflect certain features of every Japanese FXS 
patient. Macrocephaly is also a well-known feature 
in FXS patients, was also common in our case series. 
Prevalence of epilepsy (Patient 7) is compatible with 
those described in the previous report.10
The IQ of male FXS ranges between 35 and 55 
with a mean around 40.11 In the present case series, four 
of seven patients have DQ/IQ under 35. Japanese FXS 
patients have lower IQ/DQ scores, which may be due 
to a small sample size and that physicians conduct FXS 
genetic testing for patients with more severe intellectual 
disability than those in other countries. Hyperactivity 
and autistic spectrum disorders symptoms, which are 
well-known behavioral features in FXS patients, were 
also common in our case series. Generalizability was 
limited because of the small sample size, but the clini-
cal features in Japanese FXS patients might have the 
same well-known features in previous reports on FXS 
patients in other countries.
The sample size of the present study is small; 
thus, this may not reflect every Japanese FXS patient. 
However, this is the first clinical case series conducted 
in Japan. In the present study, most physicians ordered 
FXS genetic testing for suspicious cases because of 
clinical manifestations. Clinical features such as the 
macrocephaly, long face, large ears, and hyperactivity 
may be common features in Japanese FXS patients, but 
these features are also seen in patients with other disor-
ders. In many countries, FXS genetic testing is first-tier 
Table 2. Comparison between clinical features of present fragile X syndrome case series and recent review
Clinical characteristics
Prevalence
Present series Recent review (Ciaccio et al. 2017)10
Macrocephaly 4/5 (80%) 81%
Long face 5/6 (83%) 83%
Large ears 5/6 (83%) 72–78%
Mandibular prognathia 4/6 (66%) 80%
ADHD/hyperactivity 5/7 (71%) 50–66%
ASD 6/7 (86%) 30–50%
Intellectual disability 7/7 (100%) ~100%
Seizure 1/7 (14%) 10–20%
ADHD, attention deficit–hyperactivity disorder; ASD, autistic spectrum disorder.
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testing for patients with intellectual disabilities.12, 13 
Genetic testing should be performed on a wider range 
of intellectually disabled cases to diagnose more FXS 
patients in Japan. FXS genetic testing has been accepted 
as national health insurance and has been widely used 
in Japan now. The knowledge of the clinical features of 
FXS patients obtained in this study might be useful for 
increasing the diagnostic rate and understanding of FXS 
patients.
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